Launch of Galenica Diagnostics: Acquisition of Labor Team completed
Werte in diesem Artikel
Galenica AG
/ Key word(s): Takeover
Werbung Werbung Press release
Galenica has successfully completed the acquisition of Diagnostics Group GmbH (Labor Team Group including labor team w ag), one of Switzerland’s leading diagnostic service providers. The transaction was completed on 9 September 2025 with the approval of the Federal Competition Commission (COMCO) around two months after the acquisition was announced. By purchasing Labor Team, Galenica is entering the diagnostics business. Werbung Werbung Management and laboratory expertise on the Board of DirectorsIn future, Labor Team will be managed as an independent “Galenica Diagnostics” business unit in the Products & Care segment. The company will continue to operate on the market as a legally independent entity and brand. The new Board of Directors of labor team w ag brings together the management experience of the Galenica Group and specialist laboratory expertise. The current chairman of the board of directors, Ole Wiesinger, will continue to ensure stability in this role. Thomas Szuran, Chief Products & Home Care at Galenica, Julian Fiessinger, CFO of Galenica as well as Christian Rebhan, CEO Tentamus Group, and Ralph Panoff (current) are valuable additions to the board. Rahel Kubik, who has been a member of the Board of Directors to date, will be stepping down from the Board. Labor Team and Galenica would like to thank her for her dedication over the past years. The current management team of Labor Team headed by CEO Alain M. Cahen will maintain operational responsibility. Expanding the healthcare networkIn acquiring Labor Team, Galenica is adding a leading diagnostic service provider with a strong market position to its healthcare network. In addition to the existing offerings in the area of drugs and products for the physician market, it will also be possible to offer innovative laboratory services as a single provider. Werbung Werbung In the long term, Galenica is planning to develop an innovative range of selected diagnostic laboratory services within the scope of the regulatory possibilities in pharmacies. This will further strengthen healthcare provision in Switzerland. Further details: Press release dated 02 July 2025 Dates for the diary
For further information, please contact
Welcome to the Galenica network! Around 8,000 employees at Galenica work tirelessly to improve the health and well-being of the people of Switzerland every day. With its pharmacies, pharmaceutical logistics providers, products, services and home care, Galenica has a broad and successful position in the market. We are shaping the future of healthcare in collaboration with our strong partners – by drawing on the diverse skills and extensive expertise of our entire network. Our ambition is to fulfil the needs of customers and patients in the Swiss healthcare market seamlessly, efficiently and personally. Galenica is listed on the Swiss Stock Exchange (SIX Swiss Exchange, GALE, security number 36,067,446). Additional information about Galenica can be found at www.galenica.com.
End of Media Release |
Language: | English |
Company: | Galenica AG |
Untermattweg 8 | |
3027 Bern | |
Switzerland | |
Phone: | +41 058 852 81 11 |
E-mail: | info@galenica.com |
Internet: | https://www.galenica.com |
ISIN: | CH0360674466 |
Listed: | SIX Swiss Exchange |
EQS News ID: | 2194402 |
End of News | EQS News Service |
|
2194402 10.09.2025 CET/CEST
Ausgewählte Hebelprodukte auf Galenica
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Galenica
Der Hebel muss zwischen 2 und 20 liegen
Name | Hebel | KO | Emittent |
---|
Name | Hebel | KO | Emittent |
---|
Nachrichten zu Galenica AG
Analysen zu Galenica AG
Datum | Rating | Analyst | |
---|---|---|---|
11.02.2013 | Galenica verkaufen | Vontobel Research | |
18.01.2013 | Galenica verkaufen | Vontobel Research | |
03.12.2012 | Galenica reduce | Vontobel Research | |
15.08.2012 | Galenica reduce | Vontobel Research | |
14.08.2012 | Galenica neutral | Sarasin Research |
Datum | Rating | Analyst | |
---|---|---|---|
01.12.2010 | Galenica buy | Vontobel Research | |
17.09.2010 | Galenica buy | Vontobel Research | |
02.09.2010 | Galenica buy | Vontobel Research | |
27.08.2010 | Galenica buy | Vontobel Research | |
18.08.2010 | Galenica buy | Vontobel Research |
Datum | Rating | Analyst | |
---|---|---|---|
14.08.2012 | Galenica neutral | Sarasin Research | |
10.07.2012 | Galenica neutral | Sarasin Research | |
09.07.2012 | Galenica hold | Vontobel Research | |
27.06.2012 | Galenica hold | Vontobel Research | |
13.03.2012 | Galenica neutral | Sarasin Research |
Datum | Rating | Analyst | |
---|---|---|---|
11.02.2013 | Galenica verkaufen | Vontobel Research | |
18.01.2013 | Galenica verkaufen | Vontobel Research | |
03.12.2012 | Galenica reduce | Vontobel Research | |
15.08.2012 | Galenica reduce | Vontobel Research | |
26.07.2012 | Galenica reduce | Vontobel Research |
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Galenica AG nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen